Stockreport

Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering

Dianthus Therapeutics, Inc.  (DNTH) 
PDF NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnolog [Read more]